Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Beyond survival: Multisystem long-term outcomes following HSCT in chronic granulomatous disease.

Journal of human immunity·2026

Same author

Allo-defensive, multiplex base-edited, anti-CD38 CAR T cells for 'off-the-shelf' immunotherapy.

Haematologica·2025

Same author

Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia.

The New England journal of medicine·2025

Same author

Base edited "universal" donor CAR T-cell strategies for acute myeloid leukaemia.

Leukemia·2025

Same author

Long-term outcomes of genome-edited "universal" CAR19 T cells for relapsed/refractory B-ALL at a single pediatric center.

Blood advances·2025

Same author

Safety and Diagnostic Utility of Brain Biopsy and Metagenomics in Decision-Making for Patients with Inborn Errors of Immunity (IEI) and Unexplained Neurological Manifestations.

Journal of clinical immunology·2025

Same journal

Harnessing the Vaginal Microbiome: A New Frontier in the Prevention of Sexually Transmitted Infections.

Expert reviews in molecular medicine·2026

Same journal

Beyond the stomach: Exploring the role of <i>Helicobacter pylori</i> in pushing precancerous lesions to colorectal cancer and the therapeutic potential of probiotics.

Expert reviews in molecular medicine·2026

Same journal

Microchimerism: The Hidden Cellular Dialogue Between Mother and Fetal That Shapes Lifelong Immunity.

Expert reviews in molecular medicine·2026

Same journal

Advances in m6A Modification in Pregnancy-Related Disorders and Female Reproductive Endocrine Diseases.

Expert reviews in molecular medicine·2026

Same journal

Dysregulation of the urea cycle - potential targets for treatment and diagnosis in prostate cancer.

Expert reviews in molecular medicine·2026

Same journal

RAGE-Mediated Signaling in Gynecological Disorders: Review of Molecular Mechanisms and Therapeutic Perspectives.

Expert reviews in molecular medicine·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Mar 30, 2026

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

Engineered T cell therapies.

Anne-Christine Field¹, Waseem Qasim¹

¹Molecular Immunology Unit,Institute of Child Health (ICH),University College London (UCL),30 Guilford Street,London WC1N 1EH,UK.

Expert Reviews in Molecular Medicine

|November 5, 2015

Summary

This summary is machine-generated.

T cell gene therapy is expanding beyond inherited immune disorders to treat cancers and infectious diseases. Research reviews viral vectors and explores new tools like transposons and genome editing for engineered T cell therapies.

More Related Videos

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Published on: February 1, 2013

Related Experiment Videos

Last Updated: Mar 30, 2026

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Published on: February 1, 2013

Area of Science:

Immunology
Gene Therapy
Oncology

Background:

Gene therapy for inherited immune disorders has advanced.
There is a growing need for T cell gene therapy for other conditions.
T cells are amenable to ex vivo genetic modification.

Purpose of the Study:

To review clinical experiences with T cell gene therapy.
To discuss the potential of novel gene delivery and editing technologies.

Main Methods:

Review of clinical trials using γ-retroviral and lentiviral vectors.
Consideration of transposon-based vectors and genome editing tools.

Main Results:

Pioneering clinical trials have yielded safety and feasibility data.
Information on the in vivo persistence of engineered T cells has been gathered.

Conclusions:

T cell gene therapy is a promising field with expanding applications.
Future directions include integrating transposons and genome editing for enhanced therapies.